scholarly journals Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics

Biosensors ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 17 ◽  
Author(s):  
Anastasiya V. Bartosh ◽  
Dmitriy V. Sotnikov ◽  
Olga D. Hendrickson ◽  
Anatoly V. Zherdev ◽  
Boris B. Dzantiev
Keyword(s):  
Limit Of Detection ◽  
Simultaneous Detection ◽  
Optimal Location ◽  
Lateral Flow ◽  
Immunochromatographic Test ◽  
Equilibrium Conditions ◽  
Lateral Flow Assays ◽  
Lateral Flow Tests ◽  
The Impact

The presented study is focused on the impact of binding zone location on immunochromatographic test strips on the analytical parameters of multiplex lateral flow assays. Due to non-equilibrium conditions for such assays the duration of immune reactions influences significantly the analytical parameters, and the integration of several analytes into one multiplex strip may cause an essential decrease of sensitivity. To choose the best location for binding zones, we have tested reactants for immunochromatographic assays of lincomycin, chloramphenicol, and tetracycline. The influence of the distance to the binding zones on the intensity of coloration and limit of detection (LOD) was rather different. Basing on the data obtained, the best order of binding zones was chosen. In comparison with non-optimal location the LODs were 5–10 fold improved. The final assay provides LODs 0.4, 0.4 and 1.0 ng/mL for lincomycin, chloramphenicol, and tetracycline, respectively. The proposed approach can be applied for multiplexed assays of other analytes.

scholarly journals Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics

2019 ◽  
Author(s):  
Anastasiya V. Bartosh ◽  
Dmitriy V. Sotnikov ◽  
Olga D. Hendrickson ◽  
Anatoly V. Zherdev ◽  
Boris B. Dzantiev
Keyword(s):  
Limit Of Detection ◽  
Simultaneous Detection ◽  
Optimal Location ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Immunochromatographic Test ◽  
Equilibrium Conditions ◽  
Lateral Flow Tests ◽  
The Impact

The presented study is focused on the impact of binding zones locations at immunochromatographic test strips into analytical parameters of multiplex lateral flow assay. Due to non-equilibrium conditions for such assays the duration of immune reactions influences significantly on analytical parameters, and the integration of several analytes into one multiplex strip may cause essential decrease of sensitivity. To choose the best location of binding zones, we have tested reactants for immunochromatographic assays of lincomycin, chloramphenicol, and tetracycline. The influence of the distance to the binding zones on the intensity of coloration and limit of detection (LOD) was rather different. Basing on the obtained data, the best order of binding zones was chosen. In comparison with non-optimal location the LODs were 5-10 fold improved. The final assay provides LODs 0.4, 0.4 and 1.0 ng/mL for lincomycin, chloramphenicol, and tetracycline, respectively. The proposed approach can be applied for multiassays of other analytes.

scholarly journals Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2

2021 ◽  
Author(s):  
Bianca A. Trombetta ◽  
Savannah E. Kandigian ◽  
Robert R. Kitchen ◽  
Korneel Grauwet ◽  
Pia Kivisäkk Webb ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Limit Of Detection ◽  
Lateral Flow ◽  
Test Accuracy ◽  
Predictive Values ◽  
Public Resource ◽  
Attractive Option ◽  
Lateral Flow Assays ◽  
The Cost ◽  
The Impact

Abstract Background: COVID-19 has resulted in significant morbidity and mortality worldwide. Lateral flow assays can detect anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies to monitor transmission. However, standardized evaluation of their accuracy and tools to aid in interpreting results are needed.Methods: We evaluated 20 IgG and IgM assays selected from available tests in April 2020. We evaluated the assays’ performance using 56 pre-pandemic negative and 56 SARS-CoV-2-positive plasma samples, collected 10-40 days after symptom onset, confirmed by a molecular test and analyzed by an ultra-sensitive immunoassay. Finally, we developed a user-friendly web app to extrapolate the positive predictive values based on their accuracy and local prevalence.Results: Combined IgG+IgM sensitivities ranged from 33.9% to 94.6%, while combined specificities ranged from 92.6% to 100%. The highest sensitivities were detected in Lumiquick for IgG (98.2%), BioHit for both IgM (96.4%), and combined IgG+IgM sensitivity (94.6%). Furthermore, 11 LFAs and 8 LFAs showed perfect specificity for IgG and IgM, respectively, with 15 LFAs showing perfect combined IgG+IgM specificity. Lumiquick had the lowest estimated limit-of-detection (LOD) (0.1 mg/mL), followed by a similar LOD of 1.5 mg/mL for CareHealth, Cellex, KHB, and Vivachek.Conclusion: We provide a public resource of the accuracy of select lateral flow assays with potential for home testing. The cost-effectiveness, scalable manufacturing process, and suitability for self-testing makes LFAs an attractive option for monitoring disease prevalence and assessing vaccine responsiveness. Our web tool provides an easy-to-use interface to demonstrate the impact of prevalence and test accuracy on the positive predictive values.

scholarly journals Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2

2021 ◽  
Author(s):  
Bianca A. Trombetta ◽  
Savannah E. Kandigian ◽  
Robert R. Kitchen ◽  
Korneel Grauwet ◽  
Pia Kivisäkk Webb ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Limit Of Detection ◽  
Lateral Flow ◽  
Test Accuracy ◽  
Predictive Values ◽  
Public Resource ◽  
Attractive Option ◽  
Lateral Flow Assays ◽  
The Cost ◽  
The Impact

AbstractBackgroundCOVID-19 has resulted in significant morbidity and mortality worldwide. Lateral flow assays can detect anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies to monitor transmission. However, standardized evaluation of their accuracy and tools to aid in interpreting results are needed.MethodsWe evaluated 20 IgG and IgM assays selected from available tests in April 2020. We evaluated the assays’ performance using 56 pre-pandemic negative and 56 SARS-CoV-2-positive plasma samples, collected 10-40 days after symptom onset, confirmed by a molecular test and analyzed by an ultra-sensitive immunoassay. Finally, we developed a user-friendly web app to extrapolate the positive predictive values based on their accuracy and local prevalence.ResultsCombined IgG+IgM sensitivities ranged from 33.9% to 94.6%, while combined specificities ranged from 92.6% to 100%. The highest sensitivities were detected in Lumiquick for IgG (98.2%), BioHit for both IgM (96.4%), and combined IgG+IgM sensitivity (94.6%). Furthermore, 11 LFAs and 8 LFAs showed perfect specificity for IgG and IgM, respectively, with 15 LFAs showing perfect combined IgG+IgM specificity. Lumiquick had the lowest estimated limit-of-detection (LOD) (0.1 μg/mL), followed by a similar LOD of 1.5 μg/mL for CareHealth, Cellex, KHB, and Vivachek.ConclusionWe provide a public resource of the accuracy of select lateral flow assays with potential for home testing. The cost-effectiveness, scalable manufacturing process, and suitability for self-testing makes LFAs an attractive option for monitoring disease prevalence and assessing vaccine responsiveness. Our web tool provides an easy-to-use interface to demonstrate the impact of prevalence and test accuracy on the positive predictive values.

scholarly journals Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Bianca A. Trombetta ◽  
Savannah E. Kandigian ◽  
Robert R. Kitchen ◽  
Korneel Grauwet ◽  
Pia Kivisäkk Webb ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Limit Of Detection ◽  
Lateral Flow ◽  
Test Accuracy ◽  
Predictive Values ◽  
Public Resource ◽  
Attractive Option ◽  
Lateral Flow Assays ◽  
The Cost ◽  
The Impact

Abstract Background COVID-19 has resulted in significant morbidity and mortality worldwide. Lateral flow assays can detect anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies to monitor transmission. However, standardized evaluation of their accuracy and tools to aid in interpreting results are needed. Methods We evaluated 20 IgG and IgM assays selected from available tests in April 2020. We evaluated the assays’ performance using 56 pre-pandemic negative and 56 SARS-CoV-2-positive plasma samples, collected 10–40 days after symptom onset, confirmed by a molecular test and analyzed by an ultra-sensitive immunoassay. Finally, we developed a user-friendly web app to extrapolate the positive predictive values based on their accuracy and local prevalence. Results Combined IgG + IgM sensitivities ranged from 33.9 to 94.6%, while combined specificities ranged from 92.6 to 100%. The highest sensitivities were detected in Lumiquick for IgG (98.2%), BioHit for both IgM (96.4%), and combined IgG + IgM sensitivity (94.6%). Furthermore, 11 LFAs and 8 LFAs showed perfect specificity for IgG and IgM, respectively, with 15 LFAs showing perfect combined IgG + IgM specificity. Lumiquick had the lowest estimated limit-of-detection (LOD) (0.1 μg/mL), followed by a similar LOD of 1.5 μg/mL for CareHealth, Cellex, KHB, and Vivachek. Conclusion We provide a public resource of the accuracy of select lateral flow assays with potential for home testing. The cost-effectiveness, scalable manufacturing process, and suitability for self-testing makes LFAs an attractive option for monitoring disease prevalence and assessing vaccine responsiveness. Our web tool provides an easy-to-use interface to demonstrate the impact of prevalence and test accuracy on the positive predictive values.

Development of a Smartphone Based Reader for the Quantitative Analysis of Lateral Flow Assays

2018 ◽  
Vol 941 ◽  
pp. 2522-2527
Author(s):  
Sylvio Schneider ◽  
Martina Selig ◽  
Verena Keil ◽  
Matthias Lehmann ◽  
Andreas H. Foitzik ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Medical Devices ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Thrombotic Event ◽  
Lateral Flow ◽  
Proof Of Concept ◽  
Lateral Flow Assays ◽  
Further Development ◽  
D Dimer

Smartphones are developing into all-purposes devices. In the present work, the employment/application of smartphones as medical devices in home care and point-of-care (POC) diagnostics are investigated in the analysis of Lateral Flow Assays (LFA). A smartphone-based LFA reader was developed for the quantitative analysis of D-Dimer – a biomarker indicating e.g. thrombotic event or danger of embolism.The proof-of-concept has been shown with multiple smartphones in establishing: (I) Optimal dimensions of the LFA cell of 72.11mm distance of smartphone to D-Dimer test leading to a coefficients of variances (CV) between 0.8% and 4.2%. (II) Inter-device investigations: CVs around 13.5%; a limit of detection (LOD) of 100ng/ml (DDU) D-Dimer. (III) Inter-smartphone investigations: CV about 16%, a limit of detection (LOD) at 66.4ng/ml (DDU). (IV) Calibrations: CV and LOD of three smartphones are comparable to the commercial available LFA reader. Further development to put the multiple smartphone-based LFA reader on the market.

Bifunctional gold nanoparticles as an agglomeration-enhancing tool for highly sensitive lateral flow tests: a case study with procalcitonin

2017 ◽  
Vol 184 (10) ◽  
pp. 4189-4195 ◽  
Author(s):  
Nadezhda A. Taranova ◽  
Alexandr E. Urusov ◽  
Elchin G. Sadykhov ◽  
Anatoly V. Zherdev ◽  
Boris B. Dzantiev
Keyword(s):  
Gold Nanoparticles ◽  
Lateral Flow ◽  
Highly Sensitive ◽  
Lateral Flow Tests

scholarly journals Analytical evaluation of thirty-two SARS-CoV-2 lateral flow antigen tests demonstrates sensitivity remains with the SARS-CoV-2 Gamma lineage

2021 ◽  
Author(s):  
Konstantina Kontogianni ◽  
Daisy Bengey ◽  
Dominic Wooding ◽  
Kate Buist ◽  
Caitlin Greenland-Bews ◽  
...  
Keyword(s):  
Limit Of Detection ◽  
Lateral Flow ◽  
World Health ◽  
Genome Copy ◽  
Copy Numbers ◽  
Alpha Variant ◽  
And Performance ◽  
Antigen Tests ◽  
Health Organization ◽  
Lateral Flow Tests

AbstractThe limit of detection (LOD) of thirty-two antigen lateral flow tests (Ag-RDT) were evaluated with the SARS-CoV-2 Gamma variant. Twenty-eight of thirty-two Ag-RDTs exceeded the World Health Organization criteria of an LOD of 1.0×106 genome copy numbers/ml and performance was equivalent as with the 2020 B.1 lineage and Alpha variant.

scholarly journals A two-colour multiplexed lateral flow immunoassay system to differentially detect human malaria species on a single test line

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Jinsu Kim ◽  
Xiangkun Elvis Cao ◽  
Julia L. Finkelstein ◽  
Washington B. Cárdenas ◽  
David Erickson ◽  
...  
Keyword(s):  
Test Line ◽  
Limit Of Detection ◽  
Simultaneous Detection ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Specific Marker ◽  
Single Test ◽  
Simple Method ◽  
Human Malaria ◽  
Malaria Species

Abstract Background Malaria continues to impose a tremendous burden in terms of global morbidity and mortality, yet even today, a large number of diagnoses are presumptive resulting in lack of or inappropriate treatment. Methods In this work, a two-colour lateral flow immunoassay (LFA) system was developed to identify infections by Plasmodium spp. and differentiate Plasmodium falciparum infection from the other three human malaria species (Plasmodium vivax, Plasmodium ovale, Plasmodium malariae). To achieve this goal, red and blue colours were encoded to two markers on a single test line of strips, for simultaneous detection of PfHRP2 (red), a marker specific for P. falciparum infection, and pLDH (blue), a pan-specific marker for infections by all species of Plasmodium. The assay performance was first optimized and evaluated with recombinant malarial proteins spiked in washing buffer at various concentrations from 0 to 1000 ng mL−1. The colour profiles developed on the single test line were discriminated and quantified: colour types corresponded to malaria protein species; colour intensities represented protein concentration levels. Results The limit of detection (the lowest concentrations of malaria antigens that can be distinguished from blank samples) and the limit of colour discrimination (the limit to differentiate pLDH from PfHRP2) were defined for the two-colour assay from the spiked buffer test, and the two limits were 31.2 ng mL−1 and 7.8 ng mL−1, respectively. To further validate the efficacy of the assay, 25 human whole blood frozen samples were tested and successfully validated against ELISA and microscopy results: 15 samples showed malaria negative; 5 samples showed P. falciparum positive; 5 samples showed P. falciparum negative, but contained other malaria species. Conclusions The assay provides a simple method to quickly identify and differentiate infection by different malarial parasites at the point-of-need and overcome the physical limitations of traditional LFAs, improving the multiplexing potential for simultaneous detection of various biomarkers.

scholarly journals Monoclonal Antibodies Application in Lateral Flow Immunochromatographic Assays for Drugs of Abuse Detection

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 1058
Author(s):  
Zidane Qriouet ◽  
Yahia Cherrah ◽  
Hassan Sefrioui ◽  
Zineb Qmichou
Keyword(s):  
High Performance ◽  
Drugs Of Abuse ◽  
Limit Of Detection ◽  
Lateral Flow ◽  
Detection Sensitivity ◽  
Gas Chromatography Mass Spectrometry ◽  
Resource Limited ◽  
Short Period ◽  
Reaction Gas Chromatography ◽  
Lateral Flow Assays

Lateral flow assays (lateral flow immunoassays and nucleic acid lateral flow assays) have experienced a great boom in a wide variety of early diagnostic and screening applications. As opposed to conventional examinations (High Performance Liquid Chromatography, Polymerase Chain Reaction, Gas chromatography-Mass Spectrometry, etc.), they obtain the results of a sample’s analysis within a short period. In resource-limited areas, these tests must be simple, reliable, and inexpensive. In this review, we outline the production process of antibodies against drugs of abuse (such as heroin, amphetamine, benzodiazepines, cannabis, etc.), used in lateral flow immunoassays as revelation or detection molecules, with a focus on the components, the principles, the formats, and the mechanisms of reaction of these assays. Further, we report the monoclonal antibody advantages over the polyclonal ones used against drugs of abuse. The perspective on aptamer use for lateral flow assay development was also discussed as a possible alternative to antibodies in view of improving the limit of detection, sensitivity, and specificity of lateral flow assays.

scholarly journals Integrated Nanomaterials and Nanotechnologies in Lateral Flow Tests for Personalized Medicine Applications

Nanomaterials ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 2362
Author(s):  
Lucia Napione
Keyword(s):  
Personalized Medicine ◽  
Patient Monitoring ◽  
Low Cost ◽  
Detection Threshold ◽  
Accurate Method ◽  
Lateral Flow ◽  
Diagnostic Tools ◽  
Lateral Flow Assays ◽  
The Right ◽  
Lateral Flow Tests

The goal of personalized medicine is to target the right treatments to the right patients at the right time. Patients with a variety of cancers and other complex diseases are regularly tested as part of patient care, enabling physicians to personalize patient monitoring and treatment. Among the sought-after diagnostic tools, there is an increasing interest and need for those based on a low-cost, easy, rapid, and accurate method for the detection of specific circulating biomarkers above a detection threshold. Lateral flow tests (LFTs), enhanced by nanotechnology, can fulfil these requirements, providing a significant support to personalized patient monitoring. In this review, after a short historical synopsis of membrane-based lateral flow assays, including a description of a typical configuration of a LFT strip, a careful collection is presented of the best characterized nanotechnology approaches previously reported for the enhancement of target detection performance. The attempt is to offer an overview of currently integrated nanotechnologies in LFTs, fostering the actual future development of advantageous diagnostic devices for patient monitoring.

Sign in / Sign up

Export Citation Format

Share Document